Cellectis (XPAR:ALCLS) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:ALCLS Cellectis SA XPAR:ALCLS
56 GF Score
Price €1.31
GF Value €2.74
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Cellectis Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cellectis  (XPAR:ALCLS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Cellectis Cyclically Adjusted PS Ratio Related Terms


Cellectis Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Cellectis's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cellectis Cyclically Adjusted PS Ratio Chart

Cellectis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.32 2.42 3.37 2.11 6.27

Cellectis Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.56 2.88 5.69 3.90 3.78

XPAR:ALCLS vs VRTX, REGN, MRNA: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Cellectis's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectis Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectis's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Cellectis's Cyclically Adjusted PS Ratio falls into.


XPAR:ALCLS
56GF Score
Cellectis SA XPAR:ALCLS
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cellectis Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Cellectis's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Cellectis's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.045/123.5000*123.5000
=0.045

Current CPI (Jun. 2026) = 123.5000.

Cellectis Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.319 100.340 0.393
201612 0.212 100.650 0.260
201703 0.179 101.170 0.219
201706 0.166 101.320 0.202
201709 0.145 101.330 0.177
201712 0.135 101.850 0.164
201803 0.136 102.750 0.163
201806 0.100 103.370 0.119
201809 0.018 103.560 0.021
201812 0.020 103.470 0.024
201903 0.022 103.890 0.026
201906 0.024 104.580 0.028
201909 0.180 104.500 0.213
201912 0.094 104.980 0.111
202003 1.071 104.590 1.265
202006 0.062 104.790 0.073
202009 0.125 104.550 0.148
202012 0.274 104.960 0.322
202103 0.496 105.750 0.579
202106 0.204 106.340 0.237
202109 0.155 106.810 0.179
202112 0.235 107.850 0.269
202203 0.035 110.490 0.039
202206 0.027 112.550 0.030
202209 0.004 112.740 0.004
202212 0.344 114.160 0.372
202303 0.003 116.790 0.003
202306 0.003 117.650 0.003
202309 0.003 118.260 0.003
202312 0.004 118.390 0.004
202403 0.040 119.470 0.041
202406 0.075 120.200 0.077
202409 0.147 119.560 0.152
202412 0.165 119.950 0.170
202503 0.101 120.380 0.104
202506 0.147 121.360 0.150
202509 0.296 120.950 0.302
202512 0.089 120.890 0.091
202603 0.049 122.410 0.049
202606 0.045 123.500 0.045

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Cellectis (XPAR:ALCLS) Overvalued in 2026?

Based on GuruFocus' analysis, Cellectis stock appears to be undervalued. The current stock price of €1.31 is trading 52.2% below its estimated GF Value™ of €2.74. GuruFocus considers Cellectis to be Possible Value Trap.

Key valuation signals for XPAR:ALCLS:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €2.74 vs. price of €1.31 (52.2% below fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the XPAR:ALCLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cellectis Business Description

Address 8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
56GF Score

Get the complete analysis for XPAR:ALCLS

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.31
Price
€2.74
GF Value